| |
|
|
|
|
|
|
|
|
1. |
Record Nr. |
UNINA9910144728003321 |
|
|
Autore |
Holzgrabe U (Ulrike) |
|
|
Titolo |
NMR spectroscopy in drug development and analysis [[electronic resource] /] / U. Holzgrabe, I. Wawer, B. Diehl |
|
|
|
|
|
|
|
Pubbl/distr/stampa |
|
|
Weinheim ; ; New York ; ; Chichester, : Wiley-VCH, c1999 |
|
|
|
|
|
|
|
ISBN |
|
1-281-76421-3 |
9786611764210 |
3-527-61364-1 |
3-527-61365-X |
|
|
|
|
|
|
|
|
Descrizione fisica |
|
1 online resource (313 p.) |
|
|
|
|
|
|
Altri autori (Persone) |
|
DiehlB (Bernd) |
WawerI (Iwona) |
|
|
|
|
|
|
|
|
Disciplina |
|
|
|
|
|
|
Soggetti |
|
Drug development |
Drugs - Analysis |
Nuclear magnetic resonance spectroscopy |
Electronic books. |
|
|
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Note generali |
|
Description based upon print version of record. |
|
|
|
|
|
|
Nota di bibliografia |
|
Includes bibliographical references and index. |
|
|
|
|
|
|
Nota di contenuto |
|
NMR Spectroscopy in Drug Development and Analysis; Preface; Contributors; Contents; Chapter 1 Introduction; 1.1 The Instrument; 1.2 Principles; 1.2.1 Spectra; 1.2.2 Response; 1.2.3 Reproducibility; 1.2.4 Calibration; 1.3 Experimental; Chapter 2 NMR Spectroscopy in the European Regulatory Dossier; 2.1 Directives, Rules and Guidelines; 2.2 Information Required to Establish Quality; 2.3 Control of Starting Materials; 2.3.1 Specifications and Routine Tests; 2.3.2 Scientific Data; 2.4 Control of the Finished Product; 2.5 Stability Studies; 2.6 Concluding Remarks; Chapter 3 Analysis of Drugs |
3.1 NMR Spectroscopy in International Pharmacopoeias and Related Applications3.1.1 Polymers; 3.1.2 Biomolecules; 3.2 Identification and Quantification of Impurities in Drugs; 3.2.1 Impurities Resulting from the Synthesis Pathway; 3.2.2 Decomposition Reactions; 3.3 Quantification of Drugs in Dosage Forms; 3.3.1 Analysis of Single Drugs in Dosage Forms; 3.3.2 Analysis of Drug Mixtures in Dosage Forms; 3.3.3 Analysis of Drugs and Decomposition or Isomer Traces in |
|
|
|
|
|
|
|
|
|
|
|
Dosage Forms; 3.4 Analysis of Complex Mixtures, e. g. Excipients; 3.4.1 Phospholipids; 3.4.2 Silicones |
3.4.3 Fluorine Containing Substances3.5 Concluding Remarks; Chapter 4 pH-Dependent NMR Measurements; 4.1 Introduction; 4.2 Determination of the Site of Protonation; 4.3 Determination of Dissociation Constants and Stability Constants by NMR-Controlled Titrations; 4.4 Applications in Pharmacy; 4.4.1 Macroscopic Dissociation Equilibria; 4.4.2 Microscopic Dissociation Equilibria; Chapter 5 Complexation Behaviour of Drugs Studied by NMR; 5.1 Selfassociation of Drugs and Association with Other Components of a Formulation; 5.2 Complexation with Cations |
Chapter 6 Determination of the Isomeric Composition of Drugs6.1 Determination of the Enantiomeric Excess; 6.2 Comparison of Different CSAs; Chapter 7 On-line Coupling of HPLC or SFC; 7.1 Introduction; 7.2 HPLC-NMR Coupling; 7.2.1 Continuous-flow Measurements; 7.2.2 Stopped-flow Measurements; 7.3 SPE-HPLC-NMR Coupling; 7.4 SFE-NMR and SFC-NMR Coupling; Chapter 8 NMR of Body Fluids; 8.1 NMR of Urine - Studies of Metabolism; 8.1.1 1H NMR Spectroscopy; 8.1.2 19F NMR Spectroscopy; 8.1.3 15N NMR Spectroscopy; 8.1.4 31P NMR Spectroscopy |
8.2 NMR of Bile, Blood Plasma, Cerebrospinal and Seminal Fluids8.3 LC NMR Hyphenation; Chapter 9 NMR as a Tool in Drug Research; 9.1 Introduction; 9.2 Protein Structures from NMR; 9.3 Protein-Ligand Interactions; 9.3.1 NMR of Molecular Complexes; 9.3.2 Aspects of Binding Affinity; 9.3.3 Exchange Time Scales for NMR Parameters; 9.3.4 Transfer NOE; 9.3.5 Isotope Filters; 9.3.6 Measuring Binding Affinities by NMR; 9.3.7 Binding Site Localization; 9.3.8 Solvent-Accessible Surfaces; 9.3.9 Screening Protein-Ligand Interactions; 9.3.10 Conclusion; Chapter 10 Ligand-Cyclodextrin complexes |
10.1 Introduction |
|
|
|
|
|
|
Sommario/riassunto |
|
Since the development of the NMR spectrometer in the 1950s, NMR spectra have been widely used for the elucidation of the 2D structure of newly synthesized and natural compounds. In the 1980s, the high-resolution NMR spectrometer (> 300 Mhz) and 2D experiments were introduced, which opens up the possibility to determine the 3D structure of large molecules, especially biomolecules. However, NMR spectroscopy has been rarely applied to drug analysis.This book illustrates the power and versatility of NMR spectroscopy in the determination of impurities in and the content of drugs, the compositio |
|
|
|
|
|
|
|
| |